Capecitabine in advanced hepatocellular carcinoma

Dig Liver Dis. 2016 Oct;48(10):1260-1. doi: 10.1016/j.dld.2016.06.037. Epub 2016 Jul 18.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antimetabolites, Antineoplastic / adverse effects
  • Capecitabine / administration & dosage*
  • Capecitabine / adverse effects
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology
  • Female
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use*
  • Sorafenib
  • Survival Analysis

Substances

  • Antimetabolites, Antineoplastic
  • Phenylurea Compounds
  • Niacinamide
  • Capecitabine
  • Sorafenib